The ONLY thing that will get us above .40 cents is a
The ONLY thing that will get us above .40 cents is a partnership with at least 30 million up front. I think we'll get something "concrete" on the LymPro partner, but I don't think it will be a blockbuster up front money deal. It will be more modest than that.
What is worrying me the most is that all Gerald would need to do is give us an update on how the "conversations" with AD pharmas were going, and it would stop the blood shed. But he isn't doing that. In the wake of Gerald's under delivering on expectations, shareholders are just waiting for some indication that AD Pharmas actually like the LP002 data and that they are waiting for Lympro to be ready for use.
Even without giving specific revenue guidance, if he gave us more of an indication of how the "soft selling" process is going.....that would help....if it has been positive.
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Rocket Lab's Recent Stock Surge Shares of Rocket Lab Corp (NASDAQ: RKLB) have hit a remarkable all-time high, showcasing the company's increasing prominence in the space launch industry. This unprecedented rise in stock value can be largely attributed to a series of lucrative contracts that have instilled confidence among investors. Positive Developments Fueling Investor...
Continue Reading
Michaels Expands Offerings with The Knit & Sew Shop and The Party Shop Michaels continues to be a prominent name in North America by introducing exciting new store-in-store experiences known as The Knit & Sew Shop and The Party Shop. This strategic move not only enriches the shopping experience for customers, but also reinforces Michaels' position as the largest specialty...
Continue Reading
Liberty Hill Foundation Expands Leadership Team As Liberty Hill Foundation marks an important milestone, it has made significant changes to its executive leadership to bolster its efforts in supporting grassroots organizations in Los Angeles. This transformation is aimed at ensuring long-term sustainability and societal impact during a crucial time in history. New...
Continue Reading
GSK plc Shares Encouraging Results on Combined RSV and Shingles Vaccines GSK plc (LSE/NYSE: GSK) has just announced encouraging topline findings from an important phase 3 trial involving adults aged 50 and older. This study assessed the immunogenicity, reactogenicity, and safety of AREXVY, a vaccine for respiratory syncytial virus (RSV), when given together with SHINGRIX,...
Continue Reading
Investors Should Take Action Regarding Hasbro, Inc. Attention investors! A recent announcement has surfaced indicating a class action lawsuit against Hasbro, Inc. This legal action is initiated by Bronstein, Gewirtz & Grossman, LLC, a well-known law firm in the field of securities fraud. The firm aims to represent those individuals and entities that may have suffered...
Continue Reading
